Accueil   Diary - News   All news ElsaLys Biotech obtains 1.57 million euros

ElsaLys Biotech obtains 1.57 million euros

ElsaLys Biotech announced today that the FUI (Fonds Unique Interministériel – Single Interministerial Fund) has granted a 1.57 million euros subsidy to the TYROMAB (TYROsine kinase receptor Monoclonal AntiBody) project.


Led by a consortium headed by ElsaLys Biotech,this project seeks to validate and industrially produce an anti-TYRO3 antibody candidate for the treatment of leiomyosarcoma and metastatic bladder cancer. This should lead to two products: a candidate drug with an original mechanism of action in oncology and a new production system reducing monoclonal antibody production costs. Original in terms of its form and substance, this project provides a response to a twofold public health challenge: speeding up the development of new therapeutic antibodies against cancers and reducing their price, which notably entails decreasing their production cost.



Read the press release


By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to More details are available by clicking here I agree